Discover more from Weighted
Update on DXC Technology
Why 1.1x sounds good to us...
This is a quick update on DXC Technology. Please see our previous report here.
Do take note that the pricing of the counter have moved up substantially from our average entry price of USD 17.12. Yes, we have been averaging up our average price.
We are hopeful that the transformation is happening right now and we had reached our allocated positioning size. To see our 20203Q portfolio, please click here.
This position forms part of our Special Situation portfolio.
A few happenings and observation that is encouraging.
Ken Sharp has been appointed executive vice president and chief financial officer
There will be no more sales of additional business units, all subsidiaries earmarked for sale and had not been sold will be kept and optimised within DXC
Book to Bill ratio is at 1.1x. Revenue is finally growing again.
Paid down USD 3.5b in debt through their sale of their U.S. State and Local Health and Human Services business for USD 5.0 b
On a adjusted basis, EBIT remain positive
Adjusted free cashflow remained positive
DXC seems to be past their worst woes. Our chat with some of DXC employee clearly indicate that transformation effort is working its way down into Asia as well.
If you wish to receive more regular updates on what we are working on, do join our telegram channel.
As usual, do hit the comment button below if you have questions for us.